ARID1A alterations function as a biomarker for longer progression-free survival after anti-PD-1/PD-L1 immunotherapy

Abstract excerpt

Background Several cancer types harbor alterations in the gene encoding AT-Rich Interactive Domain-containing protein 1A (ARID1A), but there are no approved therapies to address these alterations. Recent studies have shown that ARID1A deficiency compromises mismatch repair proteins. Herein, we analyzed 3403 patients who had tumor tissue next-generation sequencing. Findings Among nine cancer subtypes with >5%...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Chromatin Remodeling and Cancer
• Share to Neuroendocrine Tumor Research Advances
• Share to Peptidase Inhibition and Analysis